Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6PMNR)

Drug Name
Ulocuplumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 3 [1]
Haematological malignancy 2B33.Y Phase 1/2 [2]
Cross-matching ID
TTD Drug ID
DM6PMNR

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Antagonist [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-X-C chemokine receptor type 4 (CXCR4) DTT CXCR4 7.415 8.304 6.284 6.972
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Multiple myeloma
ICD Disease Classification 2A83
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-X-C chemokine receptor type 4 (CXCR4) DTT CXCR4 7.10E-15 -0.4 -0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
2 ClinicalTrials.gov (NCT02472977) Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)